EGFR inhibitors are common treatments for cancer but cause severe skin problems that cannot be fully alleviated. Israel’s EMRIS is developing a topical solution to block EGFRi monoclonal antibodies and allow the patient to continue treatment without the debilitating side effects.
Skin care for cancer patients
This entry was posted in Israel's Medical Achievements. Bookmark the permalink.